T. Rowe Price Associates’s Denali Therapeutics DNLI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$92.1M Buy
6,582,295
+2,215,061
+51% +$31M 0.01% 585
2025
Q1
$59.4M Buy
4,367,234
+1,308,619
+43% +$17.8M 0.01% 670
2024
Q4
$62.3M Buy
3,058,615
+188,820
+7% +$3.85M 0.01% 686
2024
Q3
$83.6M Buy
2,869,795
+614,325
+27% +$17.9M 0.01% 604
2024
Q2
$52.4M Buy
2,255,470
+661,137
+41% +$15.4M 0.01% 711
2024
Q1
$32.7M Sell
1,594,333
-979,988
-38% -$20.1M ﹤0.01% 833
2023
Q4
$55.2M Sell
2,574,321
-317,629
-11% -$6.82M 0.01% 680
2023
Q3
$59.7M Sell
2,891,950
-553,362
-16% -$11.4M 0.01% 633
2023
Q2
$102M Sell
3,445,312
-92,466
-3% -$2.73M 0.01% 519
2023
Q1
$81.5M Sell
3,537,778
-111,110
-3% -$2.56M 0.01% 557
2022
Q4
$101M Buy
3,648,888
+170,520
+5% +$4.74M 0.02% 488
2022
Q3
$107M Sell
3,478,368
-1,131,809
-25% -$34.7M 0.02% 473
2022
Q2
$136M Sell
4,610,177
-313,248
-6% -$9.22M 0.02% 578
2022
Q1
$158M Buy
4,923,425
+287,992
+6% +$9.26M 0.02% 599
2021
Q4
$207M Sell
4,635,433
-122,532
-3% -$5.46M 0.02% 545
2021
Q3
$240M Sell
4,757,965
-145,487
-3% -$7.34M 0.02% 484
2021
Q2
$385M Sell
4,903,452
-1,154,827
-19% -$90.6M 0.04% 394
2021
Q1
$346M Sell
6,058,279
-406,547
-6% -$23.2M 0.03% 407
2020
Q4
$541M Buy
6,464,826
+2,103,851
+48% +$176M 0.06% 308
2020
Q3
$156M Buy
4,360,975
+1,738,813
+66% +$62.3M 0.02% 542
2020
Q2
$63.4M Buy
2,622,162
+1,411,123
+117% +$34.1M 0.01% 770
2020
Q1
$21.2M Buy
1,211,039
+793,883
+190% +$13.9M ﹤0.01% 1053
2019
Q4
$7.27M Sell
417,156
-23,041
-5% -$401K ﹤0.01% 1356
2019
Q3
$6.74M Sell
440,197
-40,943
-9% -$627K ﹤0.01% 1343
2019
Q2
$9.99M Sell
481,140
-202
-0% -$4.19K ﹤0.01% 1314
2019
Q1
$11.2M Buy
481,342
+4,100
+0.9% +$95.2K ﹤0.01% 1302
2018
Q4
$9.86M Buy
477,242
+1,175
+0.2% +$24.3K ﹤0.01% 1306
2018
Q3
$10.4M Buy
476,067
+112,242
+31% +$2.44M ﹤0.01% 1364
2018
Q2
$5.55M Sell
363,825
-7,981
-2% -$122K ﹤0.01% 1426
2018
Q1
$7.32M Buy
+371,806
New +$7.32M ﹤0.01% 1374